Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Stocks in news: Adani Enterprises, Cochin Shipyard, IDFC First Bank, Premier Energies, Glenmark Pharma
Markets traded subdued on the weekly expiry day, with indices ending marginally lower. Cochin Shipyard's offer for sale saw strong investor demand on its first day. Adani Enterprises' US legal case faces a likely dismissal by federal prosecutors. IDFC First Bank launched provident fund payment services through its EPFO integration. Premier Energies secured significant orders, and Glenmark Pharma launched a generic drug in the US.
Beyond generics: Glenmark resets agenda with a bold 10-year pivot to global drug innovation, says chairman Saldanha
For chairman Glenn Saldanha, the way forward is a mix of licensing deals, partnerships and Glenmark’s own commercialization in emerging markets.
Five Stocks To Buy: Adani Power, Glenmark Pharma, Tata Steel And More | July 7, 2026
Market analysts and brokerage firms have identified high-conviction trading ideas for the upcoming session, focusing on power, pharma, auto sector and chemicals.
Glenmark Pharmaceuticals Ltd stays supported
Glenmark Pharmaceuticals Ltd is quoting at Rs 2260.5, up 2.24% on the day as on 12:49 IST on the NSE. The stock is up 21.53% in last one year as compared to a 4.02% slide in NIFTY and a 15.14% slide in the Nifty Pharma index.
Glenmark Pharma jumps over 2% on launch of Olanzapine single-dose vial
Glenmark Pharma stock advanced over 2% in Monday's intra-day trade, after the company's US arm announced the launch of Olanzapine single-dose vial.
Glenmark, Granules shares gain after USFDA developments; check details here
Glenmark Pharmaceuticals and Granules India announced key developments in the US market, including a product launch and a regulatory milestone that strengthen their generics portfolios.
Glenmark launches generic Olanzapine injection in US
Glenmark Pharmaceuticals has launched a generic version of Olanzapine injection in the United States, offering a treatment for schizophrenia and bipolar disorder. This move by its US arm, Glenmark Pharmaceuticals Inc., introduces a bioequivalent alternative to Zyprexa intramuscular injection. The company aims to expand its injectable offerings and bolster its presence in the institutional market, targeting a segment with significant annual sales.
Glenmark Pharma gains as US arm launches generic Olanzapine injection
Glenmark Pharmaceuticals rose 1.13% to Rs 2,234.90 after its subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Olanzapine for Injection, 10 mg/vial, Single-Dose Vial in the United States.
Glenmark USA launches Olanzapine for Injection
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Glenmark's Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa2 IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253].
Glenmark advances multi-country Phase 3 clinical trial for Trastuzumab rezetecan
For patients with platinum-resistant ovarian cancer
Glenmark Pharmaceuticals receives six observations after US FDA inspection of Goa plant
Shares of Glenmark Pharmaceuticals Ltd ended at ₹2,204.90, down by ₹18.70, or 0.86%, on the BSE.
Glenmark Pharma arm launches generic Methylene Blue Injection in US market
Glenmark Pharmaceuticals said its subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) in single-dose vial form.